Company intelligence / Profile preview
SomaGenics
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
SomaGenics has developed proprietary short interfering RNA molecules (sshRNA®) with improved potency and pharmacokinetics compared to traditional siRNAs, without undesirable immune stimulation. The company also offers advanced platforms such as RealSeq® for highly specific detection of small RNAs, enabling biomarker discovery. Its pipeline includes two sshRNA-based therapeutic programs in development; however, no clinical trial results or late-stage assets are reported publicly. The company’s technologies have been validated through collaborations with leading academic institutions and industry partners.[1][4][5]
- Therapeutic areas
- OncologyDermatologyInfectious Diseases
- Modalities
- Short interfering RNA (siRNA)Small synthetic hairpin RNA (sshRNA)Nucleic acid-based diagnostics and therapeuticsNext-generation sequencing kits and qPCR technologies[1][2][3][5]
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on SomaGenics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SomaGenics.